The conversation happening in HR and benefits leadership right now isn’t whether to cover GLP-1 medications. It’s how – and how fast. For most organizations, the answer is more complicated than it should be, with many employers struggling to find sustainable ways to offer coverage that employees need.
For CHROs and CFOs, that gap represents something more serious than a benefits design problem. It’s financial exposure, talent risk and increasingly, a test of whether your organization can respond to a healthcare landscape that’s moving faster than the infrastructure built to manage it.
Employee demand for GLP-1s is real, the clinical evidence is compelling and the business case for coverage is only getting stronger. But the system hasn’t kept pace. According to GoodRx Research, more than 16 million Americans with commercial insurance have no coverage for any GLP-1 therapy prescribed for weight loss. Among those who do have coverage, more than 88% still face prior authorization or step therapy requirements — extra hoops that delay access, drive up administrative costs and push employees to abandon their prescriptions altogether.
The downstream costs of coverage gaps don’t disappear. They show up somewhere else on the balance sheet — in productivity losses, preventable long-term health claims and a benefits package that doesn’t always provide access to what employees need.
The question for executive leadership isn’t whether GLP-1s will reshape employer healthcare spending. They already are. The question is whether employers have the flexibility to respond in the ways that are most meaningful for their employees.
Health benefits infrastructure was built for a different era
The traditional employer health benefits model (negotiate a plan, set a formulary, then manage through the PBM) was designed for a slower-moving drug landscape. It optimized for standardization and scale and therapeutic breakthroughs that arrived gradually. But the pace of pharmaceutical innovation has accelerated, the competitive landscape is clear and consumer demand has reshaped how employers respond to breakthrough medications that can shift a plan’s entire cost profile within a single year.
That’s the environment that HR and benefits leaders are managing. A single drug class can now move markets, shift workforce health trajectories and create material cost exposure faster than any contract cycle allows. Formularies are typically set during annual renewals and expanding coverage mid-year is both operationally difficult and financially disruptive.
The result is a benefits architecture that’s structurally reactive, at a moment when the market demands something faster and more flexible.
A platform built for this moment
GoodRx Employer Direct was built on a different premise: that employers need flexibility and cost transparency as new models for delivering high-impact medications emerge alongside the traditional insurance system.
The model is straightforward. Employer contributions are applied directly at the pharmacy counter against manufacturer-sponsored discounted cash prices, in real time. That means no renegotiation, no lag in manufacturer-sponsored value and more flexibility for employers to determine which medications are right to include for their workforce demands.
Critically, the platform is built to scale across medications and manufacturer partnerships, not just solve for a single drug or therapeutic class. As the drug pipeline continues to expand, employers on GoodRx Employer Direct are building infrastructure that flexes with the landscape. GLP-1s may be the most visible example today, but they are unlikely to be the last therapy category to test whether consumer demand reimagines how employers sponsor their benefits with the rapid pace of medical innovation.
Working with Lilly to expand access to Zepbound® KwikPen®
GoodRx’s collaboration with Eli Lilly represents a meaningful expansion of employer-sponsored access to GLP-1 therapy. Through GoodRx Employer Direct, self-insured employers can subsidize Lilly’s $449 price for Zepbound KwikPen across all doses, with contributions applied seamlessly to the medication price. Employees can participate with an existing prescription from their own doctor or use GoodRx’s integrated telemedicine solution, GoodRx for Weight Loss, which offers clinical consultation, transparent medication pricing and pharmacy fulfillment in a single experience curated to each employer’s preferences.
The partnership reflects a shared belief that expanding access to breakthrough therapies requires building new pathways connecting access to care. By connecting Lilly’s manufacturer-sponsored pricing with employer funding in a single infrastructure, GoodRx and Lilly are giving employers a practical, scalable way to support their workforce needs.
The cost of waiting until open enrollment
For executive leadership, the risk of inaction can have serious consequences. Employees who lack access to the medications they need don’t simply accept the status quo. They leave for employers who offer better benefits.
GoodRx Employer Direct exists because that problem is real, it’s growing and the traditional system didn’t evolve at the pace of consumer demand. The employers gaining ground right now aren’t the ones with the most sophisticated plan designs. They’re the ones who recognized early that this is a strategic problem worth solving.
For more information on GoodRx Employer Direct, HR leaders can visit www.goodrx.com/employerdirect.